NSE: GLAND | BSE: 543245

Mid-range Performer

Download real time

1597.85 -7.00 (-0.44%)

High vol. this week

NSE 28 Mar, 2025 12:59 PM (IST)

26,325.6

Market Cap

High in industry

0.7

Beta 1Year

Very Low volatility

Gland Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for GLAND, BSE:543245 Gland Pharma Ltd.

Gland Pharma Ltd.

07 Aug 2023

1597.85

-0.44%

Healthy recovery in core markets

Buy: Gland Pharma Ltd.

Target

Motilal Oswal

Number of FII/FPI investors increased from 175 to 193 in Dec 2024 qtr.

Gland Pharma Ltd.

19 May 2023

1597.85

-0.44%

Result Update:Gland Pharma

Hold: Gland Pharma Ltd.

Target

Axis Direct

Company Outlook & Guidance: Injectable companies (HIKMA, HOSIPORA, and Aurobindo) in the US market sales grew by ~4% YoY. We expect similar growth for GLAND in the core markets over a longer period and high single-digit growth in India and RoW over a long-term outlook.

Gland Pharma Ltd. average weekly volume is high.

Gland Pharma Ltd.

25 Jan 2023

1597.85

-0.44%

Result Update:Gland Pharma

Hold: Gland Pharma Ltd.

Target

Axis Direct

We recommend a HOLD rating on the stock with a TP of Rs 1,500/share.

Gland Pharma Ltd. average weekly volume is high.

Gland Pharma Ltd.

23 Jan 2023

1597.85

-0.44%

Work in progress on multiple issues

Buy: Gland Pharma Ltd.

Target

Motilal Oswal

Gland Pharma Ltd. has an average target of 1710.00 from 2 brokers.

Gland Pharma Ltd.

30 Oct 2022

1597.85

-0.44%

Result Update:Gland Pharma

Hold: Gland Pharma Ltd.

Target

Axis Direct

We expect similar growth for GLAND in core markets over a longer period and high double digits growth in India &RoW. FY23 seems to be flat revenue growth due to increased competition and moderation demand for GLAND, therefore we recommend HOLD with TP of Rs 2,100.

Gland Pharma Ltd. has an average target of 1710.00 from 2 brokers.

Gland Pharma Ltd.

25 Jun 2022

1597.85

-0.44%

Multiple levers at play; valuations attractive

Buy: Gland Pharma Ltd.

Motilal Oswal

Gland Pharma Ltd. is trading above its 50 day SMA of 1556.2

Gland Pharma Ltd.

21 May 2022

1597.85

-0.44%

Gland

Buy: Gland Pharma Ltd.

Sharekhan

Gland Pharma Ltd. has an average target of 1710.00 from 2 brokers.

Gland Pharma Ltd.

20 May 2022

1597.85

-0.44%

Result Update:Gland Pharma

Hold: Gland Pharma Ltd.

Target

Axis Direct

We believe stock trades at rich valuations of PE of 36.2x and 30.4x for FY23E and FY24E respectively. We, therefore, recommend a HOLD rating on the stock with a target price of Rs 3,300/share.

Gland Pharma Ltd. average weekly volume is high.

Gland Pharma Ltd.

20 May 2022

1597.85

-0.44%

In line 4QFY22; robust prospects led by efforts on multiple fronts

Buy: Gland Pharma Ltd.

Target

Motilal Oswal

Gland Pharma Ltd. is trading below its 100 day SMA of 1667.8

Gland Pharma Ltd.

19 Apr 2022

1597.85

-0.44%

Well-placed to gain from the drug shortages in the US

Buy: Gland Pharma Ltd.

Target

Motilal Oswal

From the total injectables under shortage at the industry level, GLAND and ARBP are among the Indian companies that have the highest number of drugs as part of their respective portfolio. Even if drugs under shortage provide business opportunities for companies like SUNP/LPC/DRRD there is limited scope for supplies due to either...

Number of FII/FPI investors increased from 175 to 193 in Dec 2024 qtr.

No results found

VOTE: Is Gland Pharma Ltd. worth buying?

203 Votes:

Buy 80.3%

Sell 9.85%

Hold 9.85%

RESEARCH REPORTS

Hold SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf